3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. (3°)- or (4°)-3-Alkylquinolones via Heteroaromatic Claisen Rearrangement.Organic letters · 2026
   Article
2. Revisiting 2-Substituted-4(1Journal of medicinal chemistry · 2026
   Article
3. Ruthenium Complexes of Atovaquone Acting on Multiple Stages of theJournal of medicinal chemistry · 2026
   Article
4. Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria.Antimicrobial agents and chemotherapy · 2026
   Article
5. Targeting Mitochondrial Function inInternational journal of molecular sciences · 2025
   Review
6. Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.ACS infectious diseases · 2024
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

22 authors.

Funding

Abstract

Indexed as